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Abstract
Introduction Increased estrogen level has been regarded to be
a risk factor for breast cancer. However, estrogen has also been
shown to induce the expression of the tumor suppressor gene,
BRCA1. Upregulation of BRCA1 is thought to be a feedback
mechanism for controlling DNA repair in proliferating cells.
Estrogens enhance transcription of target genes by stimulating
the association of the estrogen receptor (ER) and related
coactivators to estrogen response elements or to transcription
complexes formed at activator protein (AP)-1 or specificity
protein (Sp)-binding sites. Interestingly, the BRCA1 gene lacks
a consensus estrogen response element. We previously
reported that estrogen stimulated BRCA1 transcription through
the recruitment of a p300/ER-α complex to an AP-1 site
harbored in the proximal BRCA1 promoter. The purpose of the
study was to analyze the contribution of cis-acting sites flanking
the AP-1 element to basal and estrogen-dependent regulation
of BRCA1 transcription.
Methods Using transfection studies with wild-type and mutated
BRCA1 promoter constructs, electromobility binding and shift
assays, and DNA-protein interaction and chromatin
immunoprecipitation assays, we investigated the role of Sp-
binding sites and cAMP response element (CRE)-binding sites
harbored in the proximal BRCA1 promoter.
Results We report that in the BRCA1 promoter the AP-1 site is
flanked upstream by an element (5'-GGGGCGGAA-3') that
recruits Sp1, Sp3, and Sp4 factors, and downstream by a half
CRE-binding motif (5'-CGTAA-3') that binds CRE-binding
protein. In ER-α-positive MCF-7 cells and ER-α-negative Hela
cells expressing exogenous ER-α, mutation of the Sp-binding
site interfered with basal and estrogen-induced BRCA1
transcription. Conversely, mutation of the CRE-binding element
reduced basal BRCA1 promoter activity but did not prevent
estrogen activation. In combination with the AP-1/CRE sites, the
Sp-binding domain enhanced the recruitment of nuclear
proteins to the BRCA1 promoter. Finally, we report that the
MEK1 (mitogen-activated protein kinase kinase-1) inhibitor
PD98059 attenuated the recruitment of Sp1 and
phosphorylated ER-α, respectively, to the Sp and AP-1 binding
element.
Conclusion These cumulative findings suggest that the
proximal BRCA1 promoter segment comprises cis-acting
elements that are targeted by Sp-binding and CRE-binding
proteins that contribute to regulation of BRCA1 transcription.
Introduction
Gene expression in mammary tissue is under the control of
ovarian steroids, including estrogen, which regulates tran-
scription activity of target promoters by stimulating the recruit-
ment of either the estrogen receptor (ER)-α or ER-β [1]. In the
classical pathway, the liganded ER-α homodimerizes and
AP = activator protein; ChIP = chromatin immunoprecipitation; CRE = cAMP response element; CREB = CRE-binding protein; DMEM = Dulbecco's 
modified Eagle's medium; ER = estrogen receptor; ERE = estrogen response element; FBS = fetal bovine serum; MAPK = mitogen-activated protein 
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binds directly to DNA at estrogen response elements (EREs)
[2]. The physical contact of the ER-α homodimer with DNA
facilitates the subsequent recruitment of coregulators [3]. The
latter factors contribute to chromatin reorganization and tran-
scriptional coactivation [4]. Alternatively, the ER-α can physi-
cally interact with DNA-bound protein complexes containing,
among other factors, the activator protein (AP)-1 [5], cAMP
response element (CRE [TGACGTCA])-binding protein
(CREB) [1], or specificity protein (Sp) family members [6,7].
The Sp factors have been shown to bind directly to the con-
sensus GC-rich region 5'-(G/T)GGGCGG(G/A)(G/A)-3' or
DNA-bound AP-1 transcription complexes [8].
Members of the Sp family of transcription factors exert differ-
ential effects on gene transcription. For example, Sp1 and Sp4
have been shown to act as transcriptional activators, whereas
Sp3 was reported to antagonize Sp1 activation functions by
competing for promoter occupancy [9-11]. The Sp family
members play a significant role in tissue and organ develop-
ment, because mice lacking at least one of the Sp proteins
exhibit various physiological abnormalities, including embry-
onic lethality [12], growth retardation [13,14], and sterility
[15]. Increased expression of Sp1 has been detected in gas-
tric [16,17] pancreatic [18], and breast [19] tumors. In addi-
tion to inducing the recruitment of ER to target promoters,
estrogen influences gene expression through the activation of
mitogen-activated protein kinases (MAPKs), which phosphor-
ylate the ER-α and other transcription factors including Sp1
[20] and AP-1 [2]. Phosphorylation of these factors increases
their binding affinity for cognate DNA elements or DNA-bound
coregulators [21].
The breast cancer susceptibility gene BRCA1  encodes a
phosphoprotein that is involved in the DNA damage response
[22,23] and regulation of cell cycle checkpoints [24]. About
30% to 40% of sporadic breast cancers, which represent the
vast majority (90% to 95%) of breast cancer cases, exhibit
lower or absent levels of BRCA1 in the absence of mutations
in the BRCA1 gene [25,26]. Because altered regulation of
BRCA1 may increase the likelihood of developing breast can-
cer, it is important to examine the molecular events that regu-
late normal BRCA1 expression.
In proliferating breast epithelial cells, the cellular levels of
BRCA1 mRNA and protein have been shown to increase in
response to estrogen [27-29]. The BRCA1 promoter harbors
two distinct transcriptional start sites (exon-1A and exon-1B).
However, translation of BRCA1 mRNA always starts from the
ATG codon located on exon-2 [30]. Upregulation of BRCA1
expression in response to estrogen may represent a feedback
mechanism that represses ER-signaling during the early
stages of breast tumorigenesis [31]. This interpretation is sup-
ported by evidence indicating that the BRCA1 protein
represses the transcriptional activity of the liganded ER-α and
estrogen-regulated genes [32]. However, the BRCA1 gene
appears not to be regulated by estrogen through the classical
pathway, because the BRCA1  promoter lacks canonical
EREs. Recently, our laboratory reported that estrogen stimu-
lated BRCA1 promoter activity by inducing the recruitment of
an ER-α/p300 transcription complex to an AP-1 element in
close proximity to the transcriptional start site of exon-1B
[33,34]. The objective of the present work was to elucidate the
roles played by Sp-binding and CRE-binding elements flank-
ing the AP-1 site in regulation of BRCA1 transcription.
Materials and methods
The experimental research reported in the manuscript has
been performed with the approval of the Institutional Biosafety
Committee of the University of Arizona (Tucson, AZ, USA), on
20 December 2005.
Cell culture and chemicals
MCF-7 and HeLa cells were obtained from the American Type
Culture Collection (Manassas, VA, USA) and maintained in
Dulbecco's modified Eagle's medium (DMEM)/F12 (Sigma-
Aldrich Chemical Co., St. Louis, MO, USA), supplemented
with 10% fetal bovine serum (FBS; Hyclone Laboratories,
Logan, UT, USA) as described previously [29]. Estrogen, pen-
icillin/streptomycin solution, and DMEM/F12 were purchased
from Sigma-Aldrich Chemical Co. Antibodies against ER-α,
Sp1, Sp3, and Sp4 were purchased from Santa Cruz Biotech-
nologies, Inc. (Santa Cruz, CA, USA). The antibody against
phosphorylated ER-α (Ser118) was obtained from Cell Sign-
aling (Beverly, MA, USA).
Site-directed mutagenesis
Details concerning the cloning of a 1.7-kilobase BRCA1 pro-
moter fragment into pGL3 Basic (pGL3BRCA1) are
described elsewhere [35]. Mutation of the Sp (GGGGCGG
to GCTAAG) and half-CRE ( C G T A A  t o  C t g c A )  c o r e
sequence in the BRCA1 promoter was carried out by site-
directed mutagenesis (Stragene, La Jolla, CA, USA) using the
following primers synthesized by Sigma-Genosys (The Wood-
lands, TX, USA): Sp-F-Mut: 5'-GGGTAGGctaaGAACCTGA-
GAGGCGTAAGG CG-3'; Sp-R-Mut: 5'-
CGCCTTACGCCTCTCA GGTTCttagCCTACCC-3'; CRE-F-
Mut: 5'-GGAACCTGAGAGGCtgcAGGCGTTGTGAAG-3';
and CRE-R-Mut: 5'-CTTCACAACGCCTgcaGCCTCTCAG-
GTTCC-3'. The insertion of mutations was confirmed by direct
sequencing.
Transfection studies
Experimental conditions for cell culture and transfection of
reporter plasmids were those described previously [33].
Briefly, MCF-7 and HeLa cells were cultured for 3 days in phe-
nol red-free DMEM/F12 and supplemented with 5% charcoal-
stripped FBS. Then, cells were seeded in six-well plates 24
hours before transfection using the Lipofectamine-Plus (Invit-
rogen, Carlsbad, CA, USA). Plasmids encoding renilla were
also cotransfected to account for variations in transfectionAvailable online http://breast-cancer-research.com/content/10/2/R29
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efficiency and cell density. Luciferase reporter activity was
monitored with a Luminometer 20/20 (Turner Biosystems,
Sunnyvale, CA, USA) and expressed as relative luciferase
units corrected for renilla.
DNA-protein pull-down assay
Eighty to ninety per cent confluent breast MCF-7 cells were
cultured for 3 days in phenol red-free DMEM/F12 and supple-
mented with 5% charcoal-stripped FBS. Cells were then main-
tained in phenol red-free DMEM/F12 plus vehicle with 5%
charcoal-stripped FBS with or without 10 nmol/l estrogen
before nuclear extracts were obtained using the Nuclear/Cyto-
plasmic Extract Kit and quantitated using the BCA protein
assay (Pierce Biotechnology, Rockford, IL, USA). The biotin-
labeled double stranded oligonucleotides were based on the
human BRCA1  promoter sequence. The DNA-protein pull-
down assay was performed as described previously [36].
Briefly, MCF-7 nuclear extracts were mixed with biotin-labeled
oligonucleotides and streptavidin agarose beads with 70%
slurry. After 2 hours of incubation at room temperature, beads
were centrifuged and washed with cold phosphate buffer
saline. Bound proteins were then separated on 4% to 12%
PAGE and Western blot analysis was performed with antibod-
ies against Sp1, Sp3, total ER-α, or phosphorylated ER-α. Oli-
gonucleotides used for the pull-down assay were as follows:
Sp/AP-1, forward: 5'-GGGTAGGGGCGGAACCTGAGAG-
GCGTAA-3'; Sp/AP-1, reverse: 5'-TTACGCCTCTCAGGT-
TCCGCCCCTACCC-3'; Sp-Mut/AP-1, forward: 5'-
GGGTAGGctaaGAACCTGAGAGGCGTAA-3'; and Sp-Mut/
AP-1, reverse: 5'-TTACGCCTCTCAGGTTCttagCCTACCC-
3'.
Electrophoretic mobility binding and shift assays
The procedure used for electromobility binding assay was
described previously [33]. Cells were plated in 6-well Costar
tissue culture plates in DMEM plus 5% charcoal-stripped
FBS. After 24 hours, cells were cultured in control DMEM plus
vehicle or 10 nmol/l estrogen. Then, cells were trypsinized and
washed with ice-cold phosphate buffer saline. Cells were
resuspended in ice-cold 25 mmol/l Hepes buffer containing
1.5 mmol/l EDTA, 1 mmol/l DTT, 0.5 mmol/l PMSF and 5 μg/
ml aprotinin, and placed on ice for 10 minutes. Cells were pel-
leted and resuspended in 1 ml ice-cold 25 mmol/l Hepes
buffer containing 1.5 mmol/l EDTA, 10% (vol/vol) glycerol, 1
mmol/l DTT, 0.5 mmol/l PMSF, and 5 μg/ml aprotinin. The cell
suspension was transferred to a mortar for drilling with a
Teflon pestle until more than 90% of the cells in a 2 μl aliquot
were unable to exclude trypan blue. After centrifugation, cell
pellets were resuspended in 150 μl ice-cold 25 mmol/l Hepes
buffer containing 1.5 mmol/l EDTA, 10% (vol/vol) glycerol, 0.5
mol/l KCl, 1 mmol/l DTT, 0.5 mmol/L PMSF and 5 μg/ml apro-
tinin, and placed on ice with intermittent vortexing. Cell debris
was removed by centrifugation. Supernatants containing
nuclear protein were stored at -70°C. Nuclear protein concen-
tration was determined using the BCA protein assay (Pierce
Chemical Company). Oligonucleotides used for binding and
shift assays are summarized in Table 1. The complementary
oligonucleotides were annealed then phosphorylated at the 5'-
end with [γ-32 P]ATP and T4 polynucleotide kinase. Unincorpo-
rated nucleotides were removed using the TE-10 spin col-
umns (Clontech Laboratories Inc., Mountain View, CA, USA).
Binding assays were performed by incubating 5 μg nuclear
protein in the binding buffer then incubated with the labeled
oligonucleotides for 20 minutes. For supershift assays, anti-
bodies (Affinity Bioreagents, Golden, CO, USA) were incu-
bated with 1 μg nuclear extracts for 2 hours before addition of
labeled oligonucleotides. For cold competition, a 100-fold
excess of the respective unlabeled oligonucleotides was
added to the binding reaction 10 minutes before addition of
the labeled oligonucleotides. For supershift assays, antibodies
(Santa Cruz Biotechnologies) were incubated with 1 μg
nuclear extracts for 2 hours before addition of labeled oligonu-
cleotides. For cold competition, a 100-fold excess of the
respective unlabeled oligonucleotides was added to the bind-
ing reaction 10 minutes before addition of the labeled oligonu-
cleotides. Samples were electrophoresed through a 5%
nondenaturing polyacrylamide gel at 200 V for 90 minutes.
Finally, the gel was dried and exposed to a phosphor screen,
and digital phosphorimages were retrieved using the Storm
system (Molecular Dynamics, Sunnyvale, CA, USA).
Chromatin immunoprecipitation assay and real-time 
PCR
Chromatin immunoprecipitation assay and real-time PCR were
carried out as described previously [34,37]. Briefly, MCF-7
cells were prepared in phenol red-free DMEM/F12 supple-
mented with 5% charcoal-stripped FBS for 3 days. After treat-
ment with control DMEM plus vehicle or 10 nmol/l estrogen,
chromatin was crosslinked with formaldehyde (1% final con-
centration) for 10 minutes at room temperature and subse-
quently glycine was added to quench the formaldehyde
crosslinking. Cells were then harvested and resuspended in
lysis buffer (1% SDS, 10 mmol/l EDTA, 50 mmol/l Tris-HCl,
and protease inhibitor cocktail). After sonication (10 × 15 sec-
onds), samples were diluted in chromatin immunoprecipitation
(ChIP) buffer (1% Triton X-100, 2 mmol/l EDTA, 150 mmol/l
NaCl, 20 mmol/l Tris-HCl, and protease inhibitor cocktail).
Dilutions of chromatin preparations were reserved as either
input (no antibody) or used for immunoprecipitation with the
desired antibody or IgG as a negative control. The chromatin
immunoprecipitation was conducted utilizing the Magna ChIP
kit (17–611) obtained from Millipore (Billenca, MA, USA), in
accordance with the protocol provided. Briefly, the sonicated
samples were immunoprecipitated overnight at 4°C with the
antibodies and G magnetic beads. The magnet beads were
pelleted and sequentially washed with a low salt immune com-
plex wash buffer, high salt immune complex wash buffer, LiCl
immune complex wash buffer, and TE buffer. The protein-DNA
complexes were eluted and crosslinking was reversed by incu-
bation with ChIP elution buffer and proteinase K for 2 h atBreast Cancer Research    Vol 10 No 2    Hockings et al.
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62°C, followed by incubation for 10 minutes at 95°C. The free
DNA was then purified using the provided spin columns.
PCR primers used to amplify the BRCA1  promoter region
flanking the Sp/AP-1/CRE binding sites were as follows: for-
ward: 5'-CTGACAGATGGGTATTCTTTGACG-3'; and
reverse: 5'-GCATATTCCAGTTCC TATCACGAG-3' (171
base pairs). The iTaq SYBR Green Supermix reagents (Bio-
Rad, Hercules, CA, USA) were used as described by the man-
ufacturer. Reactions were run at a final volume of 25 μl con-
sisting of 12.5 μl of 2× SYBR Green Supermix with ROX (0.4
mmol/l each of dATP, dCTP, dGTP, and dTTP, 50 U/ml iTaq
DNA polymerase, 6 mmol/l Mg2+, SYBR Green I, and ROX ref-
erence dye), 1 μl each of forward and reverse primers added
at a final concentration of 200 nM, 2 μl DNA, and 8.5 μl nucle-
ase-free double-distilled water. The ABI 5700 sequence
detection system and comparative CT method were used to
quantify the relative differences in PCR. BRCA1  promoter
amplicons were normalized to input.
Statistical analysis
Results of transfection studies and real-time PCR from ChIP
assays are presented as means ± standard error of the mean.
Statview, the SAS Institute (Cary, NC, USA) statistical analy-
sis software was used for analysis of variance. Comparison of
means following a significant (P < 0.05) analysis of variance
test was performed by Fisher's protected least significant dif-
ference test.
Results
The primary objective of this study was to examine whether
cis-acting elements flanking an AP-1 site located in the proxi-
mal BRCA1 promoter played a role in the basal and estrogen-
dependent regulation of BRCA1 transcription. We mapped
immediately upstream from the AP-1 site a GC-rich region
located at positions -41/-36 (GGGGCGGAA) that shared
perfect homology to the consensus Sp-binding sequence (5'-
[G/T]GGGCGG [G/A] [G/A]-3') [8] (Figure 1). We also
mapped a half-CRE-binding site (5'-CGTAA-3') immediately
downstream (-23/-27) from the AP-1 element. Previous inves-
tigations from our laboratory have documented that estrogen-
dependent stimulation of BRCA1 transcription required the
assembly of an ER-α/p300 complex at the AP-1 site [33].
Because Sp-binding factors and CRE-binding factors have
been shown to cooperate with AP-1 in regulation of transcrip-
tion, we examined the role played by these sites in controlling
basal and estrogen-induced BRCA1 promoter activity. Breast
cancer MCF-7 cells were transiently transfected with either a
reporter-luciferase construct containing 1.7 kilobase of the
wild-type BRCA1 promoter (pGL3BRCA1, -1552 to +140
Table 1
BRCA-1 Oligonucleotides used for binding and shift assays
Promoter element Oligonucleotides
AP-1/CRE Sense: 5'-AACCTGAGAGGCGTAAGGCGT-3',
Antisense: 5'-ACGCCTTACGCCTCTCAGGTT-3';
Sp/AP-1/CRE Sense: 5'-GGGTAGGGGCGGAACCTGAGAGGCGTAAGGCGT-3',
Antisense: 5'-ACGCCTTACGCCTCTCAGGTTCCGCCCCTACCC-3';
Sp-Mut/AP-1/CRE Sense: 5'-GGGTAGGctaaGAACCTGAGAGGCGTAAGGCGT-3',
Antisense: 5'-ACGCCTTACGCCTCTCAGGTTCttagCCTACCC-3'
Sp/AP-1-Mut/CRE Sense: 5'-GGGTAGGGGCGGAACtatAGAGGCGTAAGGCGT-3',
Antisense: 5'-ACGCCTTACGCCTCTataGTTCCGCCCCTACCC-3';
Sense: 5'-GGGTAGGGGCGGAACCactaAGGCGTAAGGCGT-3',
Antisense: 5'-ACGCCTTACGCCTtagtGGTTCCGCCCCTACCC-3';
Intervening AP-1/CRE sequences: Sense: 5'-GGGTAGGGGCGGAACCTGAtctGCGTAAGGCGT-3',
Antisense: 5'-ACGCCTTACGCagaTCAGGTTCCGCCCCTACCC-3';
Sense: 5'-GGGTAGGGGCGGAACCTGAGAttaGTAAGGCGT-3',
Antisense: 5'-ACGCCTTACtaaTCTCAGGTTCCGCCCCTACCC-3';
Sp/Ap-1/CRE-Mut Sense: 5'-GGGTAGGGGCGGAACCTGAGAGGCtgcAGGCGT-3',
Antisense: 5'-ACGCCTgcaGCCTCTCAGGTTCCGCCCCTACCC-3';
Sense: 5'-GGGTAGGGGCGGAACCTGAGAGGCGTcttGCGT-3',
Antisense: 5'-ACGCaagACGCCTCTCAGGTTCCGCCCCTACCC-3';
AP, activator protein; CRE, cAMP response element; Sp, specificity protein.Available online http://breast-cancer-research.com/content/10/2/R29
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from +1 on exon-1b) or the pGL3BRCA1 construct carrying
mutated Sp (pSpmut, 5'-GGctaaGAA-3') or CRE (pCREmut,
5'-CtgcA-3').
In MCF-7 cells transfected with pGL3-BRCA1, the treatment
with estrogen induced (about 2.3-fold) BRCA1  promoter
activity (Figure 2a) as compared with the control vehicle
(DMEM), thus confirming the results of previous findings from
our laboratory [34]. However, basal reporter activity was
reduced by about 80% in MCF-7 cells transfected with pSp-
mut. We observed a small increase (1.2-fold; P < 0.10) in
BRCA1 promoter activity upon treatment with estrogen, but
this stimulation was considerably lower than that observed in
cells transfected with the wild-type pGL3 BRCA1 promoter
construct. Conversely, the mutation of the half CRE-binding
site reduced by about 35% basal BRCA1 promoter activity
but did not interfere with estrogen-dependent activation
(about 2.0-fold) of BRCA1 transcription. These results clearly
highlighted the differential role of the Sp site compared with
the half-CRE in the estrogen-dependent regulation of BRCA1.
The efficacy of the transfection conditions and estrogen treat-
ment were confirmed by the activation of transcription from a
positive control promoter-luciferase construct harboring three
consensus EREs (p3XERE; Figure 2b).
Based on this information, we analyzed the cooperativity
between the Sp site and ER-α in estrogen-activation of the
BRCA1 promoter. For these experiments, we selected the
Hela cell line because it does not express ER-α and in previ-
ous studies [34], we successfully used this system to examine
estrogen-regulated BRCA1 expression. In preliminary
experiments, we ascertained that the cotransfection of Hela
cells with p3XERE plus an empty vector (pCR3.1) did not yield
measurable luciferase activity (Figure 3a). Compared with
control vehicle (DMEM), the treatment with estrogen stimu-
lated luciferase reporter activity in Hela cells cotransfected
with a vector containing the cDNA cassette for ER-α (pERα)
Figure 1
Regulatory sites of the human BRCA1 promoter Regulatory sites of the human BRCA1 promoter. A specificity protein 
(Sp) consensus site located upstream of an activator protein (AP)-1 
element in the intervening sequence between exon-1a and exon-1b 
contributes to basal and estrogen-regulated transcription. A cAMP 
response element (CRE) site located downstream of the AP-1 contrib-
utes to basal regulation. Numbers in parenthesis for the Sp, AP-1, and 
CRE elements are base pairs from the initiation of transcription (+1) on 
exon-1b. Nucleotides in boxes represent the sequence and spatial 
arrangement of the Sp, AP-1, and CRE domains. Arrows flanking the 
Sp/AP-1/CRE sites indicate the position of oligonucleotides used for 
real-time amplification after chromatin immunoprecipitation assays. The 
specific sequences of oligonucleotides are reported in the Materials 
and methods section. pGL3BRCA-1 represents a 1.692 kilobase 
BRCA1 promoter-luciferase (LUC) construct used in transfection stud-
ies. This promoter fragment extends from +140 base pairs to – 1.552 
kilobases from the +1 of exon-1b. Details of the recruitment of a p300/
ER-α/SRC-1 complex to the AP-1 site are described elsewhere [33].
Figure 2
Sp site contributes to estrogen-dependent activation of the BRCA1 promoter in breast cancer MCF-7 cells Sp site contributes to estrogen-dependent activation of the BRCA1 promoter in breast cancer MCF-7 cells. (a) Cells were precultured for 3 days in 
phenol red-free Dulbecco's modified Eagle's medium containing 5% charcoal dextran-stripped fetal bovine serum (DMEM). Then, MCF-7 cells were 
transiently transfected with pGL3BRCA-1, pSpmut, or pCREmut. Cells were cultured in control vehicle (DMEM) or DMEM plus 10 nmol/l 17β-estra-
diol (E2) for 24 hours. (b) The treatment with E2 induced promoter activity from a positive control vector (p3xERE) transfected into MCF-7 cells. 
Bars represent mean luciferase units corrected for the internal control renilla ± standard error from three independent experiments performed in 
quadruplicate. Asterisks indicate significant E2 activation (*P < 0.05) of promoter activity as compared with vehicle control (DMEM) in cells trans-
fected with pGL3BRCA-1, pSpmut, or pCREmut.Breast Cancer Research    Vol 10 No 2    Hockings et al.
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plus p3XERE. These results confirmed the validity of the Hela
cell line as a model system to study the regulation of BRCA1
by estrogen. In Hela cells transfected with pGL3BRCA1 plus
the empty vector pCR3.1, the treatment with estrogen did not
induce BRCA1 promoter activity, although it was stimulated
about 2.0-fold upon cotransfection with pERα (Figure 3b). In
Hela cells cotransfected with the pSpmut construct alone, the
basal promoter activity was reduced by 80%, and estrogen
activation was reduced in magnitude from 2.0-fold to 1.4-fold
(P < 0.05). These results confirmed the important role of the
crosstalk between the Sp site and ER-α in basal and estrogen-
dependent regulation of BRCA1 transcription.
Next, we examined whether the Sp sequence influenced the
recruitment of nuclear factors to the adjacent region of the
BRCA1 promoter harboring the AP-1 and CRE sites. BRCA1
oligonucleotides were coincubated with nuclear extracts
obtained from MCF-7 cells cultured in control vehicle (DMEM)
or in the presence of estrogen. The results of electromobility
binding assays indicated that estrogen stimulated the binding
of nuclear factors to the BRCA1 oligonucleotide harboring the
AP-1 and CRE sites as evidenced by the increase in intensity
of a DNA:protein complex (complex A; Figure 4a). However,
we observed a striking increase in the intensity of this complex
when nuclear extracts were coincubated with the BRCA1 oli-
gonucleotide spanning the Sp-, AP-1, and CRE domains.
Moreover, a second complex (complex B) of lower molecular
weight was visualized by gel electrophoresis after incubation
of nuclear extracts with the Sp/AP-1/CRE oligonucleotide.
These results suggested that the complex B probably com-
prised Sp proteins.
The role played by the Sp, AP-1, and CRE sites in the recruit-
ment of nuclear factors was further investigated in competition
studies with oligonucleotides harboring mutations for each
site (Figure 4b). Compared with the wild-type labeled BRCA1
oligonucleotide, the incubation of nuclear extracts with cold
wild-type Sp/AP-1/CRE oligonucleotide reduced the binding
by nuclear factors (Figure 4c; lane 3). Conversely, the coincu-
bation with cold oligonucleotides harboring mutated Sp, AP-1,
or CRE differentially restored binding as compared to the wild-
type labeled control (lanes 4 to 10). The most significant
recovery of binding was observed with cold oligonucleotides
mutated for Sp1 (lane 4), AP-1 (lane 5), and CREB (lanes 9
and 10). These cumulative data confirmed that the Sp, AP-1,
and CRE sites played an important role in the formation of tran-
scription complexes at this segment of the BRCA1 promoter.
To test whether the GC-box was a binding site for Sp factors
and the ER-α, we performed DNA-protein pull-down assays.
Nuclear extracts harvested from control (DMEM) and estro-
gen-treated MCF-7 cells were incubated with BRCA1 oligo-
nucleotides comprising the GC-box. Western blots revealed
the constitutive occupancy of Sp-1, Sp3, and ER-α in control
vehicle (DMEM) cells (Figure 5a). For the Sp3 protein, we vis-
ualized two doublets of approximately 60 and 100 kDa, which
represent the two short and two long forms from different
translational initiation [38]. A similar pattern for Sp3 has been
reported following Western blotting of cellular extracts
obtained from MCF-7 cells [39,40]. The treatment with estro-
gen increased the binding levels of Sp1 and ER-α protein, but
not the association of Sp3. The incubation of nuclear extracts
with BRCA1 oligonucleotides mutated for the Sp-binding site
(Spmut) reduced significantly the binding by Sp1 and Sp3,
but minimally reduced the association of ER-α. These results
suggested that Sp binding was not required for the recruit-
ment of the ER-α to the adjacent AP-1 site.
Figure 3
Sp site contributes to E2-dependent activation of the BRCA1 promoter in Hela cells expressing exogenous ER-α Sp site contributes to E2-dependent activation of the BRCA1 promoter in Hela cells expressing exogenous ER-α. (a) Hela cells were cotransfected 
with pGL3BRCA-1 or pSpmut containing a mutated specificity protein (Sp) site plus the empty vector pCR3.1 or pERα. Transfected cells were cul-
tured in Dulbecco's modified Eagle's medium containing 5% charcoal dextran-stripped fetal bovine serum plus vehicle (DMEM) or DMEM plus 10 
nmol/l 17β-estradiol (E2) for 24 hours. (b) Hela cells were cotransfected with an empty plasmid (PCR3.1) plus p3xERE or p3XERE plus a vector 
containing the cDNA for the estrogen receptor (ER)-α (pERα). Bars represent mean luciferase units corrected for the internal control renilla ± stand-
ard error from four independent experiments performed in quadruplicate. Asterisks indicate significant E2 activation (*P < 0.05) of BRCA1 promoter 
activity as compared with vehicle control (DMEM).Available online http://breast-cancer-research.com/content/10/2/R29
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Interactions of CREB proteins with the BRCA1 promoter
region containing the Sp/AP-1/CRE sequences were investi-
gated by gel electromobility shift assay. Nuclear proteins were
incubated with the Sp1/CRE or Sp/Ap1/CRE oligonucle-
otides and, upon gel separation, we observed (Figure 5b) a
pattern of retarded bands (A and B) that was similar to that
depicted in Figure 4a. Upon coincubation with an antibody for
CREB, we visualized a slower migrating band suggesting this
protein was associated with the Sp/CRE or Sp/AP-1/CRE oli-
gonucleotide. These findings suggested that the Sp site or
estrogen treatment did not influence the constitutive recruit-
ment of CREB to the AP-1/CRE region.
Figure 4
Sp site enhances the binding of nuclear proteins to the BRCA1 promoter Sp site enhances the binding of nuclear proteins to the BRCA1 promoter. (a) Nuclear extracts normalized to 5 μg of nuclear protein obtained from 
MCF-7 cells were incubated with 32P-labeled BRCA1 promoter oligonucleotides containing the activator protein (AP)-1/cAMP response element 
(CRE) or the Sp plus AP-1/CRE sites. MCF-7 cells were cultured for 3 hour in control vehicle (DMEM) or DMEM plus 10 nmol/l 17β-estradiol (E2). 
FP, free probe (lane 1). (b, c) In competition studies, nuclear extracts from MCF-7 cells cultured in the presence of E2 were incubated with 32P-
labeled BRCA1 oligonucleotides containing the wild-type specificity protein (Sp)/AP-1/CRE sequences in the absence (lane 2) or presence (100-
fold) of competing cold wild-type Sp/AP-1/CRE oligonucleotide (lane 3), or 100-fold of competing cold oligonucleotides mutated for Sp (lane 4), 
AP-1 (lanes 5 and 6), intervening sequences between AP-1 and CRE (lanes 7 and 8), and CRE (lanes 9 and 10). The arrows indicate the DNA:pro-
tein complexes visualized by electromobility binding assay.Breast Cancer Research    Vol 10 No 2    Hockings et al.
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Further confirmation of the interactions of Sp1, Sp3, Sp4, ER-
α, and CREB with the BRCA1 promoter was obtained by
ChIP assay followed by real-time PCR analysis. The treatment
with estrogen increased the occupancy of Sp1, Sp4, and ER-
α. The association of Sp3 and CREB was slightly increased by
estrogen but not to a significant degree as compared with
control DMEM (Figure 5c). These in vivo results comple-
mented those obtained with DNA-pull down and electro-
Figure 5
Estrogen stimulates the recruitment of Sp to a GC-rich region in the BRCA1 promoter Estrogen stimulates the recruitment of Sp to a GC-rich region in the BRCA1 promoter. (a) Nuclear protein extracts (200 μg) were obtained from 
MCF-7 cells cultured for 1.5 hours in Dulbecco's modified Eagle's medium containing 5% charcoal dextran-stripped fetal bovine serum containing 
vehicle (DMEM) or DMEM plus 10 nmol/l 17β-estradiol (E2). DNA:protein complexes were generated by coincubation of nuclear extracts with the 
wild-type specificity protein (Sp)1/activator protein (AP)-1 oligonucleotide or the same oligonucleotide harboring a mutated Sp (Spmut) and sepa-
rated by SDS-PAGE. The recruitment of Sp1, Sp3, or estrogen receptor (ER)-α was visualized by Western blotting with specific antibodies. Panels 
are representative of two independent experiments. Numbers represent molecular weight markers (kDa). (b) Nuclear extracts normalized to 5 μg of 
nuclear protein obtained from MCF-7 cells were incubated with 32P-labeled BRCA1 promoter oligonucleotides containing the AP-1/CRE or the Sp 
plus AP-1/CRE sites. MCF-7 cells were cultured for 3 hours in control vehicle (DMEM) or DMEM plus 10 nmol/l E2. FP, free probe (lane 1). Arrows 
indicate DNA:protein complexes (A and B) visualized by electromobility binding assay, and cAMP response element (CRE)-binding protein(CREB)/
DNA complexes supershifted with the CREB antibody. IgG, preimmune immunoglobulin control. (c) Basal and E2-induced recruitment of Sp1, Sp3, 
Sp4, and ER-α to the BRCA1 region containing the Sp, AP-1, and CRE sites was examined by chromatin immunoprecipitation assay followed by 
real-time PCR, as described in Materials and methods. The columns represent mean amplification products corrected for input ± standard error 
(bars) and normalized to vehicle control (DMEM). Asterisks indicate statistically significant (P < 0.05) induction of factor recruitment by E2 as com-
pared with vehicle control DMEM.Available online http://breast-cancer-research.com/content/10/2/R29
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phoretic mobility shift assay experiments and corroborated the
role of Sp1, Sp4, and ER-α, and of CREB, respectively, in
estrogen-regulated and basal BRCA1 transcription.
Exposure to estrogen has been shown to activate signaling
cascades, including the MAPK kinase (MEK)/MAPK phospho-
rylation pathway that leads to phosphorylation of ER-α and
related coactivators [41]. Therefore, we examined whether the
MEK/MAPK pathway modulated the binding of Sp1 and ER-α
to the BRCA1 promoter regions comprising the Sp and AP-1
sequences. Compared with MCF-7 cells cultured in control
vehicle (DMEM), the treatment with estrogen stimulated the
binding of Sp1 and ER-α. This effect was counteracted by the
cotreatment with estrogen plus the MEK1 kinase inhibitor
PD98059 (Figure 6). The constitutive binding of Sp1 and ER-
α to the BRCA1 oligonucleotide was not influenced by the
treatment with the PD98059 compound alone. As a positive
control, we measured the association of phosphorylated ER-α,
whose binding to the BRCA1 oligonucleotide was reduced
upon cotreatment with estrogen plus PD98059. These data
suggested that the recruitment of Sp1 and ER-α to the region
of the BRCA1 promoter comprising respectively the Sp and
AP-1 binding elements was mediated through MEK-depend-
ent activation of phosphorylation.
Discussion
Understanding how estrogen regulates BRCA1 expression
may contribute to clarifying the role played BRCA1 under nor-
mal physiological conditions and pathophysiological perturba-
tions that predispose to breast cancer. Previous studies from
our laboratory documented that estrogen stimulated BRCA1
expression by inducing the recruitment of an ER-α/p300 com-
plex at an AP-1 site located close to the transcription start site
of exon-1b [33]. The objective of this study was to define the
role of Sp and CRE binding sites flanking the AP-1 element.
The Sp-binding domain (5'-GGGGCGGAA-3') shared homol-
ogy with the Sp1 consensus sequence (5'-[G/T]GGGCGG
[G/A] [G/A]-3'). We found that mutation of the Sp site
reduced basal and estrogen-dependent BRCA1  promoter
activity in MCF-7 cells expressing endogenous ER-α. In trans-
fected Hela cells expressing exogenous ER-α, the mutation of
the Sp site led to a striking reduction in basal activity and
reduced the estrogen activation. Cumulative data from
DNA:protein binding and ChIP assays with BRCA1 oligonu-
cleotides spanning the GC-rich and AP-1 domain suggested
that estrogen stimulated the recruitment of Sp-1, Sp4, and ER-
α but did not affect the constitutive occupancy by Sp-3. There-
fore, the estrogen-dependent activation of the proximal
BRCA1  promoter requires the intact Sp-binding site and
appears to be mediated by increased occupancy of Sp1/Sp4
and ER-α as compared with Sp3.
Previous studies have documented that Sp3 can both
enhance and inhibit transactivation. For example, the estrogen-
dependent regulation of the VEGFR2  (vascular endothelial
growth factor receptor 2) promoter was primarily regulated by
ER-α/Sp3 and ER-α/Sp4, but not Sp1 [42]. Conversely,
recent findings by the same group [43] documented a role for
Sp1, Sp3, and Sp4 in regulating the VEGFR1 gene. Similarly,
other reports corroborated a role for ER-α/Sp1 in estrogen-
dependent activation of the interleukin-1α [44], insulin-like
growth factor-1 [45], and cdc25A [46] gene promoter. Our
results indicate that Sp1 and Sp4 play a specific role in estro-
gen-dependent regulation of BRCA1 transcription. Interest-
ingly, mutation of the Sp site did not prevent the recruitment of
the ER-α to BRCA1 oligonucleotides harboring the AP-1
domain, but it reduced transcriptional activity. These findings
suggest that the estrogen-induced association of Sp1 and
Sp4 at the GC-box may be functionally required for estrogen-
mediated transactivation of the BRCA1 promoter. The obser-
vation that the Sp-binding site enhanced the recruitment of
nuclear proteins to BRCA1 oligonucleotides comprising the
AP-1 and CRE elements suggests the Sp site may increase
the stability of the ER-α/p300 complex recruited at the adja-
cent AP-1 site. In electromobility shift assays, we observed
constitutive recruitment of CREB to a half-CRE (5'-CGTAA-3')
located just downstream from the AP-1 motif. However, the
constitutive occupancy by CREB was not altered by the estro-
gen treatment or the presence of the upstream Sp-binding
site.
Figure 6
The MEK-1 inhibitor reduces the E2-induced binding of Sp1 and ER-α  to the BRCA1 promoter The MEK-1 inhibitor reduces the E2-induced binding of Sp1 and ER-α 
to the BRCA1 promoter. Nuclear protein extracts (200 μg) were 
obtained from MCF-7 cells cultured for 1.5 hours in Dulbecco's modi-
fied Eagle's medium containing 5% charcoal dextran-stripped fetal 
bovine serum containing vehicle (DMEM), or DMEM plus 10 nmol/l 
17β-estradiol (E2), the MEK-1 (mitogen-activated protein kinase 
kinase-1) inhibitor PD98059, or E2 plus PD98059. DNA:protein com-
plexes were generated by coincubation of nuclear extracts with the 
wild-type specificity protein (Sp)1/activator protein (AP)-1 oligonucle-
otide and separated by SDS-PAGE. The recruitment of Sp1, total ER-
α, or phosphorylated ER-α was visualized by Western blotting with 
specific antibodies. Panels are representative of two independent 
experiments. Numbers indicate molecular weight markers (kDa).Breast Cancer Research    Vol 10 No 2    Hockings et al.
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One possible model that integrates the current results is
depicted in Figure 7. Activation of BRCA1 transcription by
estrogen may be dependent on the increased interaction
between Sp1, Sp4, and ER-α bound respectively to the Sp
and AP-1 elements located in the proximal region of the
BRCA1 promoter. The occupancy by CREB at the half-CRE
may serve as an ancillary factor that regulates constitutive
activity. Interactions between ER-α, Sp1, and Sp4 may trigger
the subsequent recruitment of cofactors such as p300, which
can function as a histone acetyltransferase [4], thus leading to
estrogen-dependent activation of the BRCA1  gene. This
model finds support in the experimental evidence that mutation
of the Sp or AP-1 [33] element prevented the estrogen-
dependent activation of the BRCA1 promoter.
The role of Sp proteins has been proposed to be promoter
selective and dependent on the presence of flanking
sequences [42]. The Sp1 factor has been demonstrated to
interact physically with the ER-α and ER-β [7], but only the ER-
α/Sp1 interaction led to transcriptional activation of estrogen-
responsive genes, such as Hsp27 [6], cad [47], and cathep-
sin-D [48]. Conversely, ER-α/Sp1 interactions played a mini-
mal role in activation of VEGFR2, and ER-α/Sp3 and ER-α/
Sp4 were critical factors [42]. In this study, we found that the
treatment with estrogen increased the binding of the BRCA1
promoter by Sp1 and Sp4, but it did not alter the levels of
bound Sp3. Similar to other genes involved in the oncogenic
process [49,50], the relative occupancy ratio between Sp
proteins may play a critical role in transcriptional regulation of
the BRCA1 gene. For example, elevated Sp3 levels have been
shown to promote pancreatic and breast cancer cell growth
by inhibiting transcription of growth inhibitory genes including
thosse encoding the cyclin-dependent kinase inhibitor p27
and the type II receptor for transforming growth factor-β
[8,51]. Moreover, pancreatic cells transfected with small inhib-
itory RNA targeting Sp3 exhibited increased cell cycle distri-
bution in G0/G1 and decreased distribution in S phase [8].
Conversely, Sp1 sites were required for activation of the p21
promoter [52]. Based on the observation that Sp1-mediated
transcriptional activation can be repressed by Sp3 [53], a shift
in the Sp1/Sp4 versus Sp3 binding ratio may alter normal
estrogen regulation of the BRCA1 gene. The model depicted
in Figure 7 of cooperative interactions between DNA-bound
Sp proteins and ER-α recruited at an AP-1 site is similar to that
reported for the E2F1 promoter, whose transactivation by the
ER-α was found to be independent of direct interactions with
promoter elements and was regulated by a multiprotein com-
plex comprising ER/Sp1/NF-Y [54].
Regulation of BRCA1 by estrogen may require activation of
the MAPK cascade. Estrogen binds to the ER-α and
stimulates MAPK-mediated phosphorylation of MEK1/2,
which in turn phosphorylates ERK1/2 (extracellular signal reg-
ulated kinase1/2) [55]. The activated ERK1/2 may add phos-
phate groups to ER-α and Sp and modulate protein-DNA or
protein-protein interactions of these factors at target promot-
ers. Our results document that activation of the MEK pathway
plays a key role in the estrogen-regulated recruitment of Sp1
and phosphorylated ER-α to the BRCA1 promoter.
Conclusion
We report that estrogen-dependent activation of BRCA1 tran-
scription is mediated by a GC-rich region, which is a binding
target for Sp proteins. The Sp-binding motif is located in close
proximity to an AP-1 site, which is a target for an ER-α/p300
complex. Estrogen stimulates the recruitment of Sp1 and Sp4,
but not Sp3, to the GC-rich region. We also provide evidence
that the AP-1 site is flanked by a CRE-binding domain that reg-
ulates constitutive expression. The close proximity of the Sp,
AP-1, and CRE-binding sites may be important for the recruit-
ment of transcriptional complexes and regulation of basal and
estrogen-dependent BRCA1 transcription. Finally, we provide
evidence that the MAPK pathway regulates the association of
Sp1 and ER-α with the BRCA1  promoter. Overall, these
results offer new evidence for both genomic and nongenomic
regulation of BRCA1 transcription activity by estrogen.
Figure 7
Proposed model for regulation of BRCA1 promoter activity Proposed model for regulation of BRCA1 promoter activity. Results suggest that specificity proteins (Sps) contribute to basal and estrogen (E2)-
dependent transactivation of the BRCA1 promoter. The Sp-binding region is a target site for multiple Sps, including Sp1, Sp3, and Sp4. However, 
our data document increased recruitment of Sp1 and Sp4, but not Sp3, in response to E2. We also document the constitutive presence of cAMP 
response element (CRE)-binding protein (CREB) at the CRE site. Arrows indicate potential interactions of Sp and CREB factors with a p300/estro-
gen receptor (ER)-α transcription complex bound to an activator protein (AP)-1 (Jun/Fos) domain [33] harbored in the BRCA1 promoter. The 
TRANSFAC/Match transcription factor database [56] was used to map the Sp, AP-1, and CRE sites.Available online http://breast-cancer-research.com/content/10/2/R29
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